FDA Strong Drug Ties-Less Monitoring – UK MHRA Mon, 6 Dec 2004 A front page article in The New York Times provides a historical perspective to the shift in FDA’s focus (in 1992) from watchdog safeguarding the public against hazardous drugs, food and medical devices, to its current role as…
Op Ed: Psychiatry on the Ropes–WP / Evidence-based Psychiatry– Multi-Discipline Conference_ NYC Mon, 4 Oct 2004 An Op Ed article in The Washington Post by Shannon Brownlee (below) nails the elite procurers of psychotropic drugs who have long denied the ominous signals of drug-induced harm: “You’d think the psychiatric research…
FDA reviews depression drugs–Intense or Cautious? WashPost/ NYT/ Herald Wed, 29 Oct 2003 The Washington Post correctly reports: “The association between antidepressants, particularly the selective serotonin reuptake inhibitors (SSRIs), and suicide has been controversial since the first SSRI, Prozac, came on the market in the late 1980s.” But stakeholders in…
October 1, 2001 Text of AHRP Amicus Brief filed with the Maryland Court of Appeals in support of the Court’s ruling against Kennedy Krieger Institute for exposing children to lead poison in an experiment. The Court of Appeals Decision Validates AHRP’s Stand Against Using Children in Harmful Research Experiments. ___________________________________________________…
Are we all going mad, or are the experts crazy? / Are psychiatric drugs an assault on the human condition? Fri, 19 Aug 2005 Below, two companion pieces: An Op Ed in the Los Angeles Times, by Stuart Kirk, a professor of social welfare at UCLA, addresses psychiatry’s conundum: the…
The Evidence base: rock of certainty or shifting sands? – BMJ Wed, 5 May 2004 Dr. John Dewhurst, has written an extraordinary article from his first-hand experience as a pharmaceutical company physician who discovered the disparity that exists between the claimed and actual evidence of drug effectiveness–and the reality-based severe,…
FDA to review “missing” drug company documents Fri, 31 Dec 2004 Related Link: Peter Breggin, MD RE: Eli Lilly’s Contentions that the BMJ Prozac Documents were Never Missing and Have No Significance In the final hours of 2004, an investigative reporter for the British Medical Journal obtained long “missing” Eli…
Prozac Revisited: Concerns About Suicides Surface – Boston Globe Eli Lilly’s denial about the risk of suicide for some patients prescribed Prozac was the subject of a series of reports in the Boston Globe. The article (Sunday, June 11) revealed the irony behind the duplicity. Dr. Martin Teicher, who first…
Unreported Paxil suicides: company abandons “No Addiction” claim Sat, 10 May 2003 GlaxoSmithKline, Britain’s biggest pharmaceutical company will change the label in the UK to reflect the severe withdrawal that its antidepressant drug, Seroxat (Paxil in US) generates in many patients. In Britain, the package label will no longer claim…
Reply to the American College of Neuropharmacology’s Report on SSRI and Suicidal Behavior in Children Jonathan Leo, Ph.D. Introduction The American College of Neuropsychopharmacology (ACNP) recently released an Executive Summary from its Task Force on SSRIs and Suicidal Behavior. The task force concluded that "taking Selective Serotonin Reuptake Inhibitors (SSRIs)…
NIMH Offers Grants to Study SSRI relation to Suicidality_FDA to Examine SSRI- Suicide in Adults Mon, 14 Nov 2005 A fifteen year struggle by critics of the drug-centered treatment paradigm in psychiatry is being indirectly validated both by the FDA and the National Institute of Mental Health who are addressing…
“The scariest thing is that nobody knows” risks of depression drugs for children Mon, 10 May 2004 Forest Laboratories, manufacturer of the antidepressant, Celexa / Lexapro, is the latest manufacturer to issue warnings (April 2004) about the possibility that “patients with major depressive disorder, both adult and pediatric, may experience…
